Update: CAR update and valuable allogeneic patent
Celyad has reported that all three patients in the first CAR dose cohort have completed the three-month safety follow up. This means a second, higher dose can now be tested. Importantly for future commercial developments, Celyad now holds a granted US patent on a method for producing allogeneic CAR T-cells. This could expand the market, while reducing the cost of goods compared to current autologous approaches. Celyad may license this technology at a premium. The updated indicative value of €953m or €99 per share rests on C-Cure cardiac cell therapy plus clinical CAR T-cell AML and MM therapies. Cash at 30 June 2015 was €124m.Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.